Artigos
Ivermectina no tratamento da COVID-19
- COVID-19
- Saiba mais...
A ivermectina é um antiparasitário indicado no tratamento de doenças como a estrongiloidíase e a oncocercose. Estudos in vitro têm mostrado efeitos antivirais, nomeadamente sobre a replicação do vírus SARS-CoV-2, mas em níveis muito superiores aos obtidos com a toma das doses aprovadas como antiparasitário.
Os dados existentes sobre o uso de ivermectina no tratamento da COVID-19 são provenientes estudos retrospetivos ou de ensaios clínicos, sendo que alguns apresentam diversas limitações metodológicas e um número muito reduzido de participantes. Os resultados existentes até à data são inconsistentes, estando a decorrer atualmente diversos ensaios. Assim sendo, não existe ainda evidência inequívoca de benefício da ivermectina, pelo que não estão definidas doses e esquemas de administração.
Ao contrário do que é atualmente preconizado na Europa e nos EUA, em alguns países da América do Sul a ivermectina tem sido incluída em regimes terapêuticos para tratamento da COVID-19.LEITURA RECOMENDADA
The COVID-19 Treatment Guidelines Panel’s Statement on the Use of Ivermectin for the Treatment of COVID-19. National Institutes of Health. Last Updated: January 14, 2021.
https://www.covid19treatmentguidelines.nih.gov/statement-on-ivermectin/
https://www.covid19treatmentguidelines.nih.gov/statement-on-ivermectin/
Evidence
Check - Is ivermectin effective in the treatment of COVID-19? COVID-19 Critical
Intelligence Unit, 23 December 2020.
https://aci.health.nsw.gov.au/__data/assets/pdf_file/0004/625090/20201223-Evidence-Check-Ivermectin-and-COVID-19.pdf
https://aci.health.nsw.gov.au/__data/assets/pdf_file/0004/625090/20201223-Evidence-Check-Ivermectin-and-COVID-19.pdf
Heimfarth L, Santos VS, Araújo AAS, Quintans-Júnior LJ,
Martins-Filho PR. Ivermectin:
Panacea or true promise for COVID-19. EXCLI J. 2020 Nov 9; 19: 1517-1519. doi:
10.17179/excli2020-3022. PMID: 33542677; PMCID: PMC7855117.
https://www.excli.de/vol19/excli2020-3022.pdf
https://www.excli.de/vol19/excli2020-3022.pdf
Ivermectin
and COVID-19. NPS Medicinewise, 3 September 2020.
https://www.nps.org.au/news/ivermectin-and-covid-19-for-hps
https://www.nps.org.au/news/ivermectin-and-covid-19-for-hps
Chaccour
C, Casellas A, Blanco-Di Matteo A, Pineda I, Fernandez-Montero A, Ruiz-Castillo
P, Richardson MA, Rodríguez-Mateos M, Jordán-Iborra C, Brew J, Carmona-Torre F,
Giráldez M, Laso E, Gabaldón-Figueira JC, Dobaño C, Moncunill G, Yuste JR, Del
Pozo JL, Rabinovich NR, Schöning V, Hammann F, Reina G, Sadaba B,
Fernández-Alonso M. The effect of early treatment with ivermectin on viral
load, symptoms and humoral response in patients with non-severe COVID-19: A
pilot, double-blind, placebo-controlled, randomized clinical trial.
EClinicalMedicine. 2021 Jan 19:100720. doi: 10.1016/j.eclinm.2020.100720. Epub
ahead of print.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7816625/pdf/main.pdf
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7816625/pdf/main.pdf
Ahmed
S, Karim MM, Ross AG, Hossain MS, Clemens JD, Sumiya MK, Phru CS, Rahman M,
Zaman K, Somani J, Yasmin R, Hasnat MA, Kabir A, Aziz AB, Khan WA. A five-day
course of ivermectin for the treatment of COVID-19 may reduce the duration of
illness. Int J Infect Dis. 2020 Dec 2;103:214-216. doi:
10.1016/j.ijid.2020.11.191. Epub ahead of print. PMID: 33278625; PMCID:
PMC7709596.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7709596/pdf/main.pdf
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7709596/pdf/main.pdf
Camprubí
D, Almuedo-Riera A, Martí-Soler H, Soriano A, Hurtado JC, Subirà C, Grau-Pujol
B, Krolewiecki A, Muñoz J. Lack of efficacy of standard doses of ivermectin in
severe COVID-19 patients. PLoS One. 2020 Nov 11;15(11): e0242184. doi:
10.1371/journal.pone.0242184.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7657540/pdf/pone.0242184.pdf
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7657540/pdf/pone.0242184.pdf
Rajter
JC, Sherman MS, Fatteh N, Vogel F, Sacks J, Rajter JJ. Use of Ivermectin Is
Associated With Lower Mortality in Hospitalized Patients With Coronavirus
Disease 2019: The Ivermectin in COVID Nineteen Study. Chest. 2021 Jan; 159(1): 85-92.
doi: 10.1016/j.chest.2020.10.009. Epub 2020 Oct 13.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7550891/pdf/main.pdf
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7550891/pdf/main.pdf